New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
07:03 EDTBDSIBioDelivery Sciences completes enrollment for Phase 3 trial of Clonidine
BioDelivery Sciences has completed enrollment of all patients required for its initial Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. The trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with PDN. This is the first of two pivotal trials that would be required for submission of a New Drug Application to the FDA. FDA has granted Fast Track designation for the program.
News For BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
17:14 EDTBDSIBioDelivery Sciences files $150M mixed securities shelf
Subscribe for More Information
10:48 EDTBDSIOptions with increasing implied volatility
Subscribe for More Information
July 1, 2015
18:39 EDTBDSIOn The Fly: After Hours Movers
UP AFTER EARNINGS: Progress Software (PRGS), up 6.6%. ALSO HIGHER: Xoom (XOOM), up 22% after announcing company to be acquired by PayPal... BioDelivery Sciences (BDSI), up 4.7% after Point72 Asset Management reports 5.5% passive stake in the company... Green Brick Partners (GRBK), up 7.5% after Third Point reports 16.9% stake in the company.
16:13 EDTBDSIPoint72 Asset Management reports 5.5% passive stake in BioDelivery Sciences
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use